Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Cancer Prev Res (Phila). 2019 Aug 26;12(12):891–902. doi: 10.1158/1940-6207.CAPR-19-0162

Figure 3:

Figure 3:

Association between use of antiviral medication for HCV and subsequent development of HCC separately among patients with cirrhosis and those without cirrhosis. Analyses were performed after inverse probability of treatment weighting (IPTW). Among patients with cirrhosis: for the comparison between DAA-only vs. IFN-only, after the IPTW, additional adjustments were performed for age, time from treatment to HCC development, Charlson comorbidity index, race, ribavirin, SVR, substance use, insurance type, and BMI. For the comparison between DAA + IFN vs. IFN-only, additional adjustment was performed for time from treatment to HCC development after IPTW. For the comparison between any DAA and IFN-only, additional adjustments were performed for age, time from treatment to HCC development, Charlson comorbidity index, gender, census region, ribavirin, SVR, insurance type, and smoking status after the IPTW. Among patients without cirrhosis, the same factors were adjusted for each comparison as was done for the patients with cirrhosis.

Abbreviations: DAA, direct acting antiviral medication; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IFN, interferon, SVR, sustained virological response